Lilly

2Q Revenues: $5.2 billion (+11%)

2Q Earnings: $958.8 million (+44%)

YTD Revenues: $10.0 billion (+12%)

YTD Earnings: $2.0 billion (+73%)

Comments: Alimta, Byetta, Cialis, Cymbalta, Forteo, Strattera, Symbyax, Xigris and Yentreve, collectively grew 21% to $1.8 billion, and accounted for 35% of total sales, up from 32% in 2Q07. Zyprexa sales in the quarter were $1.2 billion (+2%). Cymbalta sales were $654.4 million (+26%). Gemzar sales were $440.1 million (+11%). Humalog sales were up 22% to $437.9 million. Cialis sales were $362.2 million (+24%). Alimta sales were up 33% to $275.0 million. Byetta sales were up 25% to $194.7 million in quarter. The company recognized a charge of $35.0 million in quarter for acquired in-process R&D associated with the in-licensing transaction with TransPharma Medical. Restructuring costs and other charges were $88.9 million in the quarter, primarily associated with strategic exit activities related to manufacturing operations.

Bristol-Myers Squibb
 
2Q Revenues: $5.2 billion (+16%)

2Q Earnings: $764.0 million (+8%)

YTD Revenues: $10.1 billion (+19%)

YTD Earnings: $1.4 billion  (+2%)

Comments: Pharmaceutical sales in the quarter were $4.5 billion (+16%). U.S. pharma sales were $2.6 billion (+17%) due to increased sales of Plavix, Abilify growth, and the HIV and hepatitis portfolio, as well as contributions from recent product launches, Orencia and Ixempra. Plavix sales were $1.4 billion (+17%) in the quarter. Abilify sales were up 28% to $529 million. Reyataz sales were $324 million (+28%). Sustiva Franchise revenues were $282 million (+21%). Baraclude sales were $136 million (+131%).  Orencia sales were $106 million (+93%). Ixempra sales were $26 million in the quarter. R&D expenses were up 9% to $826 million in the quarter. Acquired in-process R&D charges were $32 million, related to the acquisition of Kosan Biosciences, Inc.

Christine Dingivan, M.D. has been appointed executive vice president and chief medical officer, PPD, Inc. Dr. Dingivan provides strategic direction for global regulatory affairs and pharmacovigilance, biomarker discovery sciences, Phase I, and bioanalytical and cGMP lab services. She is also responsible for medical assessment of clinical data as well as adherence to ethical standards and good lab practices.
   
Prior to joining the company, Dr. Dingivan spent 12 years with MedImmune, which was acquired by AstraZeneca in 2007. She most recently served as senior vice president of clinical development and operations, having previously held a number of roles with increasing responsibility. She oversaw strategic development and implementation of global clinical research programs across all therapeutic areas, provided senior clinical leadership for U.S. and European regulatory applications, and chaired the clinical safety monitoring committee.
   
“Exceptional scientific, leadership and communications skills define Christine Dingivan,” said Fred Eshelman, chief executive officer of PPD. “With her in-depth experience in clinical development, strategic operations and medical affairs gained during her long tenure with MedImmune, she will play a key role in helping us advance our clients’ products through development. I am pleased to welcome her to PPD.”

News from our sister sites